Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06707402Not ApplicableRecruiting

The Effects of 24-Weeks Community-based Brisk Walking in People With Parkinson's Disease

Role: collaborator

NCT03354455Not ApplicableCompleted

Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease

Role: collaborator

NCT01446549Not ApplicableCompleted

Motor Performance in Parkinson's Disease After High Intensive Exercise or Deep Brain Stimulation

Role: collaborator

All 3 trials loaded